1921
Volume 90, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Pregnant women bear the greatest burden of malaria–human immunodeficiency virus co-infection. Previous studies suggest that interaction with antiretroviral drugs may compromise antimalarial pharmacokinetics and treatment outcomes. We conducted a preliminary clinical study to assess quinine pharmacokinetics in Malian pregnant women with acute malaria who reported taking nevirapine-based antiretroviral therapy. Of seven women, six had stable concentrations of nevirapine in the plasma and one had none. Quinine concentrations were lower, and its metabolite 3-hydroxyquinine higher, in the six women with nevirapine than in the one without, and quinine concentrations were below the recommended therapeutic range in 50% of the women. This preliminary observation warrants further research to understand the impact of long-term antiretroviral therapy on the treatment of acute malaria.

[open-access] This is an Open Access article distributed under the terms of the American Society of Tropical Medicine and Hygiene's Re-use License which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.13-0655
2014-03-05
2017-11-21
Loading full text...

Full text loading...

/deliver/fulltext/14761645/90/3/530.html?itemId=/content/journals/10.4269/ajtmh.13-0655&mimeType=html&fmt=ahah

References

  1. Calvert C, Ronsmans C, , 2013. The contribution of HIV to pregnancy-related mortality: a systematic review and meta-analysis. AIDS 27: 16311639.[Crossref]
  2. ter Kuile FO, Parise ME, Verhoeff FH, Udhayakumar V, Newman RD, van Eijk AM, Rogerson SJ, Steketee RW, , 2004. The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-Saharan Africa. Am J Trop Med Hyg 71: 4154.
  3. Idemyor V, , 2007. Human immunodeficiency virus (HIV) and malaria interaction in sub-Saharan Africa: the collision of two Titans. HIV Clin Trials 8: 246253.[Crossref]
  4. Parise ME, Ayisi JG, Nahlen BL, Schultz LJ, Roberts JM, Misore A, Muga R, Oloo AJ, Steketee RW, , 1998. Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. Am J Trop Med Hyg 59: 813822.
  5. Steketee RW, Wirima JJ, Bloland PB, Chilima B, Mermin JH, Chitsulo L, Breman JG, , 1996. Impairment of a pregnant woman's acquired ability to limit Plasmodium falciparum by infection with human immunodeficiency virus type-1. Am J Trop Med Hyg 55: 4249.
  6. Filler SJ, Kazembe P, Thigpen M, Macheso A, Parise ME, Newman RD, Steketee RW, Hamel M, , 2006. Randomized trial of 2-dose versus monthly sulfadoxine-pyrimethamine intermittent preventive treatment for malaria in HIV-positive and HIV-negative pregnant women in Malawi. J Infect Dis 194: 286293.[Crossref]
  7. ter Kuile FO, van Eijk AM, Filler SJ, , 2007. Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review. JAMA 297: 26032616.[Crossref]
  8. Achan J, Talisuna AO, Erhart A, Yeka A, Tibenderana JK, Baliraine FN, Rosenthal PJ, D'Alessandro U, , 2011. Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria. Malar J 10: 144.[Crossref]
  9. Abdelrahim II, Adam I, Elghazali G, Gustafsson LL, Elbashir MI, Mirghani RA, , 2007. Pharmacokinetics of quinine and its metabolites in pregnant Sudanese women with uncomplicated Plasmodium falciparum malaria. J Clin Pharm Ther 32: 1519.[Crossref]
  10. Zhang H, Coville PF, Walker RJ, Miners JO, Birkett DJ, Wanwimolruk S, , 1997. Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine. Br J Clin Pharmacol 43: 245252.[Crossref]
  11. Mirghani RA, Hellgren U, Bertilsson L, Gustafsson LL, Ericsson O, , 2003. Metabolism and elimination of quinine in healthy volunteers. Eur J Clin Pharmacol 59: 423427.[Crossref]
  12. Pukrittayakamee S, Prakongpan S, Wanwimolruk S, Clemens R, Looareesuwan S, White NJ, , 2003. Adverse effect of rifampin on quinine efficacy in uncomplicated falciparum malaria. Antimicrob Agents Chemother 47: 15091513.[Crossref]
  13. Nyunt MM, Lu Y, El-Gasim M, Parsons TL, Petty BG, Hendrix CW, , 2012. Effects of ritonavir-boosted lopinavir on the pharmacokinetics of quinine. Clin Pharmacol Ther 91: 889895.[Crossref]
  14. Soyinka JO, Onyeji CO, Omoruyi SI, Owolabi AR, Sarma PV, Cook JM, , 2009. Effects of concurrent administration of nevirapine on the disposition of quinine in healthy volunteers. J Pharm Pharmacol 61: 439443.[Crossref]
  15. Pukrittayakamee S, Wanwimolruk S, Stepniewska K, Jantra A, Huyakorn S, Looareesuwan S, White NJ, , 2003. Quinine pharmacokinetic-pharmacodynamic relationships in uncomplicated falciparum malaria. Antimicrob Agents Chemother 47: 34583463.[Crossref]
  16. WHO, 2000. WHO Expert Committee on Malaria. World Health Organ Tech Rep Ser 892: 174.
  17. Division of AIDS (DAIDS), NIAID, 2009. DAIDS table for grading the severity of adult and pediatric adverse events. Available at: http://rsc.tech-res.com/Document/safetyandpharmacovigilance/Table_for_Grading_Severity_of_Adult_Pediatric_Adverse_Events.pdf. Accessed June 15, 2012.
  18. World Health Organization, 2009. Workshop to review and plan therapeutic efficacy studies to monitor P. falciparum and P. vivax resistance to anti-malarial drugs in the Greater Mekong Sub-region. Available at: http://www.whothailand.org/LinkFiles/Mekong_Malaria_Programme_Draft_final_report_mandaly.PDF. Accessed January 23, 2013.
  19. Snounou G, Zhu X, Siripoon N, Jarra W, Thaithong S, Brown KN, Viriyakosol S, , 1999. Biased distribution of msp1 and msp2 allelic variants in Plasmodium falciparum populations in Thailand. Trans R Soc Trop Med Hyg 93: 369374.[Crossref]
  20. Edstein MD, Prasitthipayong A, Sabchareon A, Chongsuphajaisiddhi T, Webster HK, , 1990. Simultaneous measurement of quinine and quinidine in human plasma, whole blood, and erythrocytes by high-performance liquid chromatography with fluorescence detection. Ther Drug Monit 12: 493500.[Crossref]
  21. Silverthorn CF, Parsons TL, , 2006. A validated new method for nevirapine quantitation in human plasma via high-performance liquid chromatography. Biomed Chromatogr 20: 2327.[Crossref]
  22. Orlando R, De Martin S, Pegoraro P, Quintieri L, Palatini P, , 2009. Irreversible CYP3A inhibition accompanied by plasma protein-binding displacement: a comparative analysis in subjects with normal and impaired liver function. Clin Pharmacol Ther 85: 319326.[Crossref]
  23. Sowunmi A, Salako LA, , 1996. Effect of dose size on the pharmacokinetics of orally administered quinine. Eur J Clin Pharmacol 49: 383386.[Crossref]
  24. Riska P, Lamson M, MacGregor T, Sabo J, Hattox S, Pav J, Keirns J, , 1999. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos 27: 895901.
  25. Barry M, Mulcahy F, Merry C, Gibbons S, Back D, , 1999. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet 36: 289304.[Crossref]
  26. Achan J, Kakuru A, Ikilezi G, Ruel T, Clark TD, Nsanzabana C, Charlebois E, Aweeka F, Dorsey G, Rosenthal PJ, Havlir D, Kamya MR, , 2012. Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children. N Engl J Med 367: 21102118.[Crossref]
  27. Amaratunga C, Sreng S, Suon S, Phelps ES, Stepniewska K, Lim P, Zhou C, Mao S, Anderson JM, Lindegardh N, Jiang H, Song J, Su XZ, White NJ, Dondorp AM, Anderson TJ, Fay MP, Mu J, Duong S, Fairhurst RM, , 2012. Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis 12: 851858.[Crossref]
  28. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ, , 2009. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361: 455467.[Crossref]
  29. Kyaw MP, Nyunt MH, Chit K, Aye MM, Aye KH, Lindegardh N, Tarning J, Imwong M, Jacob CG, Rasmussen C, Perin J, Ringwald P, Nyunt MM, , 2013. Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar. PLoS ONE 8: e57689.[Crossref]
  30. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM, , 2008. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 359: 26192620.[Crossref]
  31. Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, Ler Moo C, Al-Saai S, Dondorp AM, Lwin KM, Singhasivanon P, Day NP, White NJ, Anderson TJ, Nosten F, , 2012. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet 379: 19601966.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.13-0655
Loading
/content/journals/10.4269/ajtmh.13-0655
Loading

Data & Media loading...

  • Received : 11 Nov 2013
  • Accepted : 23 Nov 2013

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error